Regen BioPharma Inc logo

Regen BioPharma Inc - SERIES A

(Preferred)
NEW
OTCPK:RGBPP.PFD (USA)   Non Cum Pfd Registered Shs Series -A-
$ 0.0048 +0.00056 (+13.33%) 10:08 PM EST
At Loss
Volume:
3.98K
Avg Vol (2M):
8.24M
Trade In:
Volume:
3.98K
At Loss
Avg Vol (2M):
8.24M

Business Description

Regen BioPharma Inc logo
Regen BioPharma Inc
NAICS : 325414 SIC : 2834
ISIN : US75886M4096

Share Class Description:

RGBPP.PFD: Non Cum Pfd Registered Shs Series -A-

Total Employee Number:

1
Description
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.

Financial Strength

Name Current Vs Industry Vs History
Equity-to-Asset
-20.61
Debt-to-Equity
-0.18
Debt-to-EBITDA
-1.9
Piotroski F-Score
4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
-146.92
Distress
Grey
Safe
Beneish M-Score
-13.01
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
51.79
9-Day RSI
52.33
14-Day RSI
52.08
3-1 Month Momentum %
106.25
6-1 Month Momentum %
-89.85
12-1 Month Momentum %
-89.15

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
0.05
Quick Ratio
0.05
Days Sales Outstanding
327.49

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-80.4
Shareholder Yield %
-467.64

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin %
-368.64
Net Margin %
-302.97
EBITDA Margin %
-214.41
ROA %
-314.15
ROIC %
-20.14
3-Year ROIIC %
-0.05
Years of Profitability over Past 10-Year
3
Moat Score
3
Tariff Resilience Score
4

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio
0.04
EV-to-EBIT
-2.13
EV-to-EBITDA
-2.13
EV-to-Revenue
4.56
EV-to-FCF
-2.26
Earnings Yield (Greenblatt) %
-46.95
FCF Yield %
-467.65

GF Valueâ„¢

Regen BioPharma Inc Filings

Filing Date Document Date Form
No Filing Data

Regen BioPharma Inc Stock Events

Financials Calendars
Event Date Price ($)
Third quarter earnings results for 2026 2026-08-11 In 44 days
General meeting for 2025 2026-06-30 In 2 days
Second quarter earnings results for 2026 2026-05-14 0.00 (-45.90%)
First quarter earnings results for 2026 2026-02-13 0.00 (-27.50%)
2:1 Stock Split 2026-02-10 0.01 (+82.12%)
Annual report for 2025 2025-12-30 0.03 (+92.59%)
Emerging Growth Conference 88 2025-12-10 12:00 0.04 (+3.00%)
The Emerging Growth Conference 2025-09-24 16:25 0.02 (-30.64%)
Third quarter earnings results for 2025 2025-08-11 0.03 (-25.00%)
Emerging Growth Conference 83 2025-06-18 15:25 0.03 (+9.45%)
Show
Entries

Guru Commentaries on OTCPK:RGBPP.PFD

No articles.

Articles on Regen BioPharma Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1